| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $11,602 | 1 | 5 |
Sells | $398,298 | 18 | 95 |
| FitzPatrick Margaret M | director | 1 | $11,602 | 0 | $0 | $11,602 |
| Williams Sarah Joanne | Principal Accounting Officer | 0 | $0 | 3 | $3,025 | $-3,025 |
| Prior Stephen David | Chief Strategy Officer | 0 | $0 | 3 | $7,379 | $-7,379 |
| Day Lucy | Chief Financial Officer | 0 | $0 | 2 | $8,883 | $-8,883 |
| Chanda Sanjay | Chief Development Officer | 0 | $0 | 2 | $9,332 | $-9,332 |
| Eizen Joshua M | See Remarks | 0 | $0 | 4 | $52,978 | $-52,978 |
| Readnour Robin Shane | director | 0 | $0 | 4 | $316,700 | $-316,700 |
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Over the last 12 months, insiders at AN2 Therapeutics, Inc. have bought $11,602 and sold $398,298 worth of AN2 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at AN2 Therapeutics, Inc. have bought $10.94M and sold $3.81M worth of stock each year.
Highest buying activity among insiders over the last 12 months: FitzPatrick Margaret M (director) — $11,602.
The last purchase of 2,098 shares for transaction amount of $11,602 was made by FitzPatrick Margaret M (director) on 2026‑09‑01.
| 2026-09-09 | Sale | Readnour Robin Shane | director | 1,108 0.0032% | $6.02 | $6,675 | -15.71% | |
| 2026-09-08 | Sale | Readnour Robin Shane | director | 10,019 0.0225% | $6.02 | $60,297 | -19.23% | |
| 2026-09-03 | Sale | Readnour Robin Shane | director | 6,100 0.0139% | $6.07 | $37,026 | -18.66% | |
| 2026-09-01 | Sale | Williams Sarah Joanne | Principal Accounting Officer | 272 0.0008% | $5.53 | $1,504 | -11.22% | |
| 2026-09-01 | FitzPatrick Margaret M | director | 2,098 0.0059% | $5.53 | $11,602 | -11.22% | ||
| 2026-08-17 | Sale | Readnour Robin Shane | director | 35,402 0.0829% | $6.01 | $212,702 | -11.87% | |
| 2026-07-08 | Sale | Eizen Joshua M | See Remarks | 5,945 0.0205% | $4.17 | $24,803 | +13.83% | |
| 2026-05-29 | Sale | Williams Sarah Joanne | Principal Accounting Officer | 265 0.001% | $4.43 | $1,174 | +13.63% | |
| 2026-03-03 | Sale | Williams Sarah Joanne | Principal Accounting Officer | 327 0.0012% | $1.06 | $347 | +342.92% | |
| 2026-01-06 | Sale | Eizen Joshua M | See Remarks | 6,931 0.0239% | $1.01 | $7,014 | +324.30% | |
| 2026-01-06 | Sale | Chanda Sanjay | Chief Development Officer | 5,956 0.0206% | $1.01 | $6,027 | +324.30% | |
| 2026-01-06 | Sale | Day Lucy | Chief Financial Officer | 5,512 0.019% | $1.01 | $5,578 | +324.30% | |
| 2026-01-06 | Sale | Prior Stephen David | Chief Strategy Officer | 2,858 0.0099% | $1.01 | $2,892 | +324.30% | |
| 2026-01-05 | Sale | Eizen Joshua M | See Remarks | 17,923 0.0612% | $1.00 | $17,948 | +323.36% | |
| 2026-01-05 | Sale | Chanda Sanjay | Chief Development Officer | 3,295 0.0113% | $1.00 | $3,305 | +323.36% | |
| 2026-01-05 | Sale | Day Lucy | Chief Financial Officer | 3,295 0.0113% | $1.00 | $3,305 | +323.36% | |
| 2026-01-05 | Sale | Prior Stephen David | Chief Strategy Officer | 3,604 0.0123% | $1.00 | $3,615 | +323.36% | |
| 2025-11-04 | Sale | Eizen Joshua M | See Remarks | 2,819 0.0096% | $1.14 | $3,214 | +268.42% | |
| 2025-11-04 | Sale | Prior Stephen David | Chief Strategy Officer | 765 0.0026% | $1.14 | $872 | +268.42% | |
| 2025-06-02 | Easom Eric | Chief Executive Officer | 10,000 0.0333% | $1.07 | $10,665 | +9.43% |
| Readnour Robin Shane | director | 557467 1.4773% | $2.33M | 8 | 6 | <0.0001% |
| FitzPatrick Margaret M | director | 10708 0.0284% | $44,759.44 | 2 | 0 | +0.87% |
| Shah Rajeev M. | 3773417 9.9995% | $15.77M | 5 | 0 | +11.29% | |
| Leonard Braden Michael | 10 percent owner | 3217432 8.5261% | $13.45M | 1 | 3 | +7.62% |
| Adjuvant Global Health Technology Fund DE, L.P. | 2210735 5.8584% | $9.24M | 1 | 0 | <0.0001% | |
| Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 377542 1.0005% | $1.58M | 1 | 10 | <0.0001% |
| Aziz Kabeer | director | 377542 1.0005% | $1.58M | 1 | 10 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 300853 0.7973% | $1.26M | 9 | 1 | +12.48% |
| Easom Eric | Chief Executive Officer | 256380 0.6794% | $1.07M | 3 | 17 | +15.22% |
| Zakrzewski Joseph S | director | 125199 0.3318% | $523,331.82 | 3 | 1 | +7.58% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
AN2 Therapeutics, Inc. (ANTX) | $38,621,826 | 31 | 1.43% | $157.74M |
$41,526,694 | 30 | 23.89% | $135.61M | |
$74,231,875 | 30 | 40.62% | $183.78M |
| Increased Positions | 15 | +41.67% | 924,459 | +12.23% |
| Decreased Positions | 11 | -30.56% | 159,431 | -2.11% |
| New Positions | 6 | New | 669,045 | New |
| Sold Out Positions | 3 | Sold Out | 36,740 | Sold Out |
| Total Postitions | 40 | +11.11% | 8M | +10.12% |
| Almitas Capital Llc | $1,585.00 | 5.29% | 1.43M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $1,199.00 | 4% | 1.08M | +44,123 | +4.26% | 2025-09-30 |
| Peapod Lane Capital Llc | $654.00 | 2.18% | 589,216 | +6,446 | +1.11% | 2025-09-30 |
| Stonepine Capital Management, Llc | $626.00 | 2.09% | 563,913 | +19,419 | +3.57% | 2025-09-30 |
| Bank Of Nova Scotia | $510.00 | 1.7% | 459,194 | 0 | 0% | 2025-09-30 |
| Landscape Capital Management, L.L.C. | $507.00 | 1.69% | 456,463 | -38,933 | -7.86% | 2025-09-30 |
| Bank Of Montreal /Can/ | $469.00 | 1.56% | 422,077 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $428.00 | 1.43% | 385,597 | -13,257 | -3.32% | 2025-09-30 |
| Bank Of America Corp /De/ | $428.00 | 1.43% | 385,310 | -201 | -0.05% | 2025-09-30 |
| Blackrock, Inc. | $356.00 | 1.19% | 320,911 | +1,616 | +0.51% | 2025-09-30 |